Squarepoint
JAZZ icon

Squarepoint’s Jazz Pharmaceuticals JAZZ Stock Holding History

Squarepoint’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.74M Buy
+15,500
New +$3.4M ﹤0.01% 1831
2026
Q1 		– Sell
-4,400
Closed -$748K – 4614
2025
Q4 		$748K Buy
+4,400
New +$675K ﹤0.01% 2857

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Squarepoint's JAZZ Position: Q2 2026 in Review

Squarepoint opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2026: 53,148 shares worth $12.8M. The stake represents 0.01% of the portfolio and ranks #944 among its holdings. This is a return to the name: Squarepoint previously reported a position in JAZZ as recently as Q4 2025.

Squarepoint first reported a position in JAZZ in Q4 2015 and has held it in 29 quarters since. The position peaked at $20.5M in Q4 2018. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Squarepoint held 53,148 shares of Jazz Pharmaceuticals worth $12.8M as of Q2 2026.
  • Jazz Pharmaceuticals was a new Squarepoint position in Q2 2026.
  • Jazz Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q2 2026, its #944 holding.
  • Squarepoint first reported a position in Jazz Pharmaceuticals in Q4 2015 and has held it in 29 quarters since.
  • Squarepoint's Jazz Pharmaceuticals position peaked at $20.5M in Q4 2018.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.